What does research say about Bard and AngioDynamics ports and these problems?
Health agencies say any port can raise the risk of infection and clots, because its tube sits in a large vein. We found no FDA statement that links Bard or AngioDynamics ports to these problems.
FDA lists a few recalls of certain lots of both companies’ ports, for problems such as a wrong part, packaging that may not be sterile, or missing instructions. The recall records we read were not about the tube wearing down, infection or clots.
In the Bard cases, the judge has ruled on which expert opinions a jury may hear. In March 2026 the judge barred one expert from saying that the amount of barium sulfate in Bard ports raises the risk of clots and infection. Between March and September 2026, in three test cases, the judge turned down all or most of Bard’s requests to end the case before a trial.
Rulings like these decide what evidence may be used and whether a case can reach a jury. They are not findings that a port caused anyone’s harm. In the federal court records we read, we found no ruling that either company’s ports cause these problems.
In the AngioDynamics cases, the court set its schedule for shared expert questions to run into 2027.